Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial - Université Claude Bernard Lyon 1 Accéder directement au contenu
Article Dans Une Revue Clinical Lung Cancer Année : 2020

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial

Nicolas Girard
Jacques Cadranel
  • Fonction : Auteur
  • PersonId : 901162
Christos Chouaid
Bertrand Mennecier
  • Fonction : Auteur
Ludivine Perrier
  • Fonction : Auteur

Résumé

Osimertinib, a third-generation tyrosine kinase inhibitor, is a new therapeutic option in epidermal growth factor receptor (EGFR)-mutated non-pretreated advanced non-small-cell lung cancer (NSCLC). The tumor escape mechanisms after first-line treatment with osimertinib are partially known; most of the data being obtained by analysis of circulating tumor DNA (ctDNA) from the FLAURA phase III trial.
Fichier non déposé

Dates et versions

hal-02504807 , version 1 (11-03-2020)

Identifiants

Citer

Jaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, Aurélie Le Thuaut, Radj Gervais, et al.. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clinical Lung Cancer, 2020, 21 (1), pp.e10-e14. ⟨10.1016/j.cllc.2019.09.007⟩. ⟨hal-02504807⟩
93 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More